Migraines unlikely to increase the risk of Parkinson’s for women
Women with current or past migraines were not seen to be at a higher risk of developing Parkinson’s disease…
Articles by Andrea Lobo
Phase 2 trial of VG081821 to ease motor symptoms fully enrolled
Enrollment is complete in a Phase 2 trial of VG081821, an investigational therapy to treat early to mid-stage Parkinson’s…
Actor Ryan Reynolds headlines Parkinson’s awareness campaign
Ryan Reynolds is the face of an educational campaign aiming to raise awareness of lesser-known Parkinson’s disease symptoms: the…
Smart shoes designed to ‘walk with confidence’ available in EU, US
Sensor-equipped shoes — called NUSHU smart shoes — that are designed to support people with walking difficulties due to…
100 patients enrolled in trial of light therapy for Parkinson’s disease
Photopharmics said the first 100 patients have been enrolled in a Phase 3 trial testing its light-based therapy device,…
FDA approves fully asleep DBS surgical procedure by Medtronic
The U.S. Food and Drug Administration (FDA) has approved Medtronic’s Asleep Deep Brain Stimulation (DBS) surgery for people…
Merck, GTRI partner on gene therapy for Parkinson’s disease
Merck‘s U.S. and Canada life sciences business, MilliporeSigma, signed a memorandum of understanding with Gene Therapy Research Institution (GTRI),…
Study probes contact sports, CTE, parkinsonism links
Nearly one-quarter of deceased athletes with chronic traumatic encephalopathy (CTE), a neurodegenerative disease associated with repetitive head impacts, experienced…
Brenig raises $65M to advance LRRK2 inhibitor BT-267 to trials
Brenig Therapeutics has raised $65 million to advance its lead candidate, LRRK inhibitor BT-267, into human clinical trials as…
$6M grant aids work into calcium channel blocker to protect neurons
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $6 million grant to Lario…